$207.19−0.74 (−0.36%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
National Healthcare (NHC) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~9.0%/yr (FY21→FY25), net margin 8.1%, and free cash flow (~$148.6M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▲16.1%
1,517.8
FY21→FY25CAGR +9.0%/yr
Net income ($M)▲20.1%
122.6
one-off year: see footnoteCAGR −3.1%/yr
Free cash flow ($M)▲86.5%
148.6
FY21→FY25CAGR +59.4%/yr
Diluted EPS▲17.5%
7.67
FY21→FY25CAGR −3.9%/yr
What the receipts whisper · what a headline number hides
Share count
+1.5%
15.4mn → 15.6mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$36.4M
+32.1% YoY in FY25 · 2.4% of revenue.
Returns vs FCF
36%
$53.3M returned vs $148.6M of FCF in FY25. Buybacks + dividends covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
8¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 38.0% → 39.3%. Net margin 8.1% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,584.3 | 1,517.8 | 1,307.4 | 1,141.5 | 1,085.7 | 1,074.3 | ▲16.1% | +9.0% |
Cost of revenue | 962.2 | 921.1 | 810.9 | 712.3 | 686.2 | 666.1 | ▲13.6% | +8.4% |
Gross profit | 622.2 | 596.7 | 496.5 | 429.2 | 399.6 | 408.2 | ▲20.2% | +10.0% |
Selling, general & admin | 381.4 | 377.2 | 321.4 | 288.2 | 289.4 | 266.8 | ▲17.4% | +9.0% |
Total operating expenses | 467.2 | 468.3 | 406.6 | 371.7 | 367.7 | 357.3 | ▲15.2% | +7.0% |
Operating incomefeeds ROC rank | 154.9 | 128.4 | 89.9 | 57.5 | 31.9 | 50.9 | ▲42.8% | +26.0% |
Other income, net | −4.3 | 34.1 | 46.5 | 31.3 | −4.7 | 99.1 | — | — |
Pretax income | 150.6 | 162.4 | 136.4 | 88.7 | 27.2 | 150.0 | ▲19.1% | +2.0% |
Income tax | 34.6 | 39.8 | 34.3 | 23.4 | 7.3 | 11.0 | ▲16.0% | +38.1% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 116.0 | 122.6 | 102.1 | 65.3 | 20.0 | 139.1 | ▲20.1% | −3.1% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 7.24 | 7.67 | 6.53 | 4.34 | 1.45 | 8.99 | ▲17.5% | −3.9% |
Diluted shares (mn) | 15.96 | 15.65 | 15.60 | 15.38 | 15.45 | 15.42 | ▲0.3% | +0.4% |
| Margins | ||||||||
Gross margin20th pct in Healthcare | 39.3% | 39.3% | 38.0% | 37.6% | 36.8% | 38.0% | ▲1.3pp | +1.3pp |
Operating margin | 9.8% | 8.5% | 6.9% | 5.0% | 2.9% | 4.7% | ▲1.6pp | +3.7pp |
Net margin61st pct in Healthcare | 7.3% | 8.1% | 7.8% | 5.7% | 1.8% | 12.9% | ▲0.3pp | −4.9pp |
† TTM = trailing four quarters through 2026-09-30.FY21 effective tax rate was 7% vs a 25% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was National Healthcare's revenue last fiscal year?
National Healthcare reported revenue of $1,517.8M in fiscal 2025, up 16.1% from fiscal 2024.
What was National Healthcare's net income?
National Healthcare reported net income of $122.6M in fiscal 2025, a net margin of 8.1%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

